{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:25:27Z","timestamp":1794799527838,"version":"4.9.1"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112298","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T08:27:12Z","timestamp":1634113632000},"page":"112298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Foresight regarding drug candidates acting on the succinate\u2013GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment"],"prefix":"10.1016","volume":"144","author":[{"given":"Chengyuan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2008.08.005","article-title":"Insulin resistance, inflammation, and non-alcoholic fatty liver disease","volume":"19","author":"Tilg","year":"2008","journal-title":"Trends Endocrinol. Metab. TEM"},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003149","article-title":"Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts","volume":"17","author":"Atabaki-Pasdar","year":"2020","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1461505","article-title":"Therapeutic effects of serum extracellular vesicles in liver fibrosis","volume":"7","author":"Chen","year":"2018","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41467-019-09524-z","article-title":"Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"issue":"2 Suppl 1","key":"10.1016\/j.biopha.2021.112298_bib5","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metab. Clin. Exp."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.112298_bib11","first-page":"S11","article-title":"Natural history of nonalcoholic steatohepatitis","volume":"40","author":"Liou","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00535-003-1308-3","article-title":"Hepatocellular carcinoma with nonalcoholic steatohepatitis","volume":"39","author":"Mori","year":"2004","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH Leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib15","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep.28584","article-title":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Lonardo","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib21","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1002\/ptr.7195","article-title":"Corosolic acid ameliorates non-alcoholic steatohepatitis induced by high-fat diet and carbon tetrachloride by regulating TGF-\u03b21\/Smad2, NF-\u03baB, and AMPK signaling pathways","volume":"35","author":"Liu","year":"2021","journal-title":"Phytother. Res. PTR"},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib22","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/ptr.7055","article-title":"Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice","volume":"35","author":"Li","year":"2021","journal-title":"Phytother. Res. PTR"},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib23","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2021.112298_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.643857","article-title":"Xanthohumol ameliorates diet-induced liver dysfunction via farnesoid X receptor-dependent and independent signaling","volume":"12","author":"Paraiso","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112298_bib26","article-title":"A network pharmacology approach: Inhibition of the NF-\u03baB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats","volume":"88","author":"Sun","year":"2021","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/13880209.2021.1945112","article-title":"Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1\/NF-\u03baB p65 pathway","volume":"59","author":"Yang","year":"2021","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.biopha.2021.112298_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2021.01.002","article-title":"Hypoxia-inducible factor-2 promotes liver fibrosis in non-alcoholic steatohepatitis liver disease via the NF-\u03baB signalling pathway","volume":"540","author":"Cai","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib29","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib30","first-page":"51","article-title":"L. Smircic Duvnjak, new drugs on the block-emerging treatments for nonalcoholic steatohepatitis","volume":"9","author":"Stojsavljevic-Shapeski","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/hepr.13425","article-title":"Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib33","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41467-020-16918-x","article-title":"Hepatic HuR modulates lipid homeostasis in response to high-fat diet","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112298_bib34","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/ncomms8466","article-title":"A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism","volume":"6","author":"Xu","year":"2015","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib35","first-page":"13091","article-title":"GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses","volume":"34","author":"Li","year":"2020","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003619","article-title":"Receptors of intermediates of carbohydrate metabolism, GPR91 and GPR99, mediate axon growth","volume":"16","author":"Cherif","year":"2018","journal-title":"PLoS Biol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib38","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.molmet.2017.09.005","article-title":"Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91","volume":"6","author":"Trauelsen","year":"2017","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib42","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00015.2017","article-title":"Interorgan metabolic crosstalk in human insulin resistance","volume":"98","author":"Gancheva","year":"2018","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0000000000000080","article-title":"Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans","volume":"25","author":"Jacome-Sosa","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib44","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091575","article-title":"Molecular pathogenesis of NASH","volume":"17","author":"Caligiuri","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5152\/tjg.2018.17330","article-title":"Liver fibrosis","volume":"29","author":"Ayd\u0131n","year":"2018","journal-title":"Turk. J. Gastroenterol. Off. J. Turk. Soc. Gastroenterol."},{"key":"10.1016\/j.biopha.2021.112298_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-7113-8_11","article-title":"Isolation and culture of primary murine hepatic stellate cells","volume":"1627","author":"Weiskirchen","year":"2017","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2001-17550","article-title":"History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells","volume":"21","author":"Geerts","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.biopha.2021.112298_bib50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2018.00455","article-title":"Succinate as a regulator of hepatic stellate cells in liver fibrosis","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112298_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib52","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","article-title":"Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis","volume":"178","author":"Fallowfield","year":"2007","journal-title":"J. Immunol."},{"issue":"32","key":"10.1016\/j.biopha.2021.112298_bib53","doi-asserted-by":"crossref","first-page":"E3297","DOI":"10.1073\/pnas.1400062111","article-title":"Origin of myofibroblasts in the fibrotic liver in mice","volume":"111","author":"Iwaisako","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib54","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI88845","article-title":"Mesothelin\/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib55","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3748\/wjg.v27.i8.677","article-title":"G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment","volume":"27","author":"Yang","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm.3614","article-title":"A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice","volume":"20","author":"Oh","year":"2014","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib58","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/jhep.2003.50029","article-title":"Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations","volume":"37","author":"Yamamoto","year":"2003","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib59","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.prp.2014.07.011","article-title":"A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival","volume":"210","author":"Liu","year":"2014","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.22433","article-title":"The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in mice","volume":"48","author":"Johnson","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib61","first-page":"1299","article-title":"GPR55 deficiency is associated with increased adiposity and impaired insulin signaling in peripheral metabolic tissues","volume":"33","author":"Lipina","year":"2019","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib62","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4049\/jimmunol.1901427","article-title":"The bile acid receptor GPBAR1 modulates CCL2\/CCR2 signaling at the liver sinusoidal\/macrophage interface and reverses acetaminophen-induced liver toxicity","volume":"204","author":"Biagioli","year":"2020","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib63","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.bmcl.2011.04.091","article-title":"Discovery of a potent and selective small molecule hGPR91 antagonist","volume":"21","author":"Bhuniya","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib64","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1189\/jlb.1008618","article-title":"The role of the GPR91 ligand succinate in hematopoiesis","volume":"85","author":"Hakak","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib65","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ni.1657","article-title":"Triggering the succinate receptor GPR91 on dendritic cells enhances immunity","volume":"9","author":"Rubic","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2021.112298_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fendo.2012.00022","article-title":"The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions","volume":"3","author":"Ariza","year":"2012","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112298_bib67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2016.01.008","article-title":"Insight into SUCNR1 (GPR91) structure and function","volume":"159","author":"Gilissen","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2007.03.016","article-title":"Succinate is a paracrine signal for liver damage","volume":"47","author":"Correa","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2021.112298_bib69","doi-asserted-by":"crossref","unstructured":"Succinate Receptors (SUCNR1) as a Potential Target for Pharmacotherapy, Pharmaceutical Chemistry Journal 49(9) (2015) 573\u2013577.","DOI":"10.1007\/s11094-015-1331-8"},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbrc.2015.06.023","article-title":"Succinate causes \u03b1-SMA production through GPR91 activation in hepatic stellate cells","volume":"463","author":"Li","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6988","key":"10.1016\/j.biopha.2021.112298_bib71","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nature02488","article-title":"Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors","volume":"429","author":"He","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib72","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.tibs.2016.02.003","article-title":"Intermediates of metabolism: from bystanders to signalling molecules","volume":"41","author":"Haas","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"7444","key":"10.1016\/j.biopha.2021.112298_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11986","article-title":"Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1","volume":"496","author":"Tannahill","year":"2013","journal-title":"Nature"},{"issue":"1 Suppl","key":"10.1016\/j.biopha.2021.112298_bib74","first-page":"S61","article-title":"Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis","volume":"31","author":"Kojima","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41374-018-0177-6","article-title":"Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib76","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2017.03.028","article-title":"Multidimensional tracking of GPCR signaling via peroxidase-catalyzed proximity labeling","volume":"169","author":"Paek","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome","volume":"22","author":"Kroeze","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib78","first-page":"830","article-title":"Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: effects of DHA supplementation","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib79","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbrc.2018.01.106","article-title":"Succinate induces hepatic fibrogenesis by promoting activation, proliferation, and migration, and inhibiting apoptosis of hepatic stellate cells","volume":"496","author":"Park","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147597","article-title":"The succinate receptor GPR91 Is involved in pressure overload-induced ventricular hypertrophy","volume":"11","author":"Yang","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2021.112298_bib81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dnarep.2014.07.001","article-title":"Akt and p53R2, partners that dictate the progression and invasiveness of cancer","volume":"22","author":"Yousefi","year":"2014","journal-title":"DNA Repair"},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib82","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.ijcard.2013.07.150","article-title":"An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy","volume":"168","author":"Palomer","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib83","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123773","article-title":"Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma","volume":"19","author":"Trejo-Sol\u00eds","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib85","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3390\/ijms14022334","article-title":"Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds","volume":"14","author":"Kalimuthu","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020275","article-title":"Ixeris dentata (Thunb. Ex Thunb.) Nakai extract inhibits proliferation and induces apoptosis in breast cancer cells through Akt\/NF-\u03bab pathways","volume":"18","author":"Shin","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112298_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1621687","article-title":"Reactive oxygen species induce endothelial differentiation of liver cancer stem-like sphere cells through the activation of akt\/ikk signaling pathway","volume":"2020","author":"Zhao","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41467-019-08802-0","article-title":"A network-centric approach to drugging TNF-induced NF-\u03baB signaling","volume":"10","author":"Pabon","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2006347","article-title":"Transcriptional outcomes and kinetic patterning of gene expression in response to NF-\u03baB activation","volume":"16","author":"Zhao","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2021.112298_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2020.07.141","article-title":"GPR91 antagonist and TGF-\u03b2 inhibitor suppressed collagen production of high glucose and succinate induced HSC activation","author":"Sakai","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib91","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1101\/gad.1527307","article-title":"SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress","volume":"21","author":"Scher","year":"2007","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib92","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/bi901627u","article-title":"Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria","volume":"49","author":"Cimen","year":"2010","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023295","article-title":"Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity","volume":"6","author":"Finley","year":"2011","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.biopha.2021.112298_bib94","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1074\/jbc.M115.692244","article-title":"Sirtuin 3 (SIRT3) regulates \u03b1-smooth muscle actin (\u03b1-SMA) production through the succinate dehydrogenase-g protein-coupled receptor 91 (GPR91) pathway in hepatic stellate cells","volume":"291","author":"Li","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib95","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1128\/MCB.01658-12","article-title":"Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3","volume":"33","author":"He","year":"2013","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib96","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbadis.2015.01.014","article-title":"The pharmacology of resveratrol in animals and humans","volume":"1852","author":"Park","year":"2015","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib97","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1111\/jcmm.14320","article-title":"The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux","volume":"23","author":"Chen","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib98","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v22.i10.2931","article-title":"Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression","volume":"22","author":"Abd El-Haleim","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2021.112298_bib99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1743-7075-11-35","article-title":"Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice","volume":"11","author":"Zhu","year":"2014","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.biopha.2021.112298_bib100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-015-0139-6","article-title":"Resveratrol ameliorates hepatic steatosis and inflammation in methionine\/choline-deficient diet-induced steatohepatitis through regulating autophagy","volume":"14","author":"Ji","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib101","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res."},{"key":"10.1016\/j.biopha.2021.112298_bib102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nut.2016.09.001","article-title":"Alternative treatment methods attenuate the development of NAFLD: a review of resveratrol molecular mechanisms and clinical trials","volume":"34","author":"Charytoniuk","year":"2017","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib103","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Heeb\u00f8ll","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib104","first-page":"2092","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9111042","article-title":"Comparative effects of pterostilbene and its parent compound resveratrol on oxidative stress and inflammation in steatohepatitis induced by high-fat high-fructose feeding","volume":"9","author":"G\u00f3mez-Zorita","year":"2020","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/nu11050961","article-title":"Pterostilbene reduces liver steatosis and modifies hepatic fatty acid profile in obese rats","volume":"11","author":"Aguirre","year":"2019","journal-title":"Nutrients"},{"issue":"25","key":"10.1016\/j.biopha.2021.112298_bib107","doi-asserted-by":"crossref","first-page":"22586","DOI":"10.1074\/jbc.M101846200","article-title":"Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol","volume":"276","author":"Stivala","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jat.1260","article-title":"Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat","volume":"28","author":"Rivera","year":"2008","journal-title":"J. Appl. Toxicol. JAT"},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib109","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s12272-014-0347-z","article-title":"Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase","volume":"37","author":"Choi","year":"2014","journal-title":"Arch. Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.biopha.2021.112298_bib110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1089\/jmf.2018.4261","article-title":"Effects of piceatannol and resveratrol on sirtuins and hepatic inflammation in high-fat diet-fed mice","volume":"22","author":"Lee","year":"2019","journal-title":"J. Med. Food"},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib111","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/09168451.2014.921551","article-title":"Synthesis of glycosides of resveratrol, pterostilbene, and piceatannol, and their anti-oxidant, anti-allergic, and neuroprotective activities","volume":"78","author":"Sato","year":"2014","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072081","article-title":"The dietary antioxidant piceatannol inhibits adipogenesis of human adipose mesenchymal stem cells and limits glucose transport and lipogenic activities in adipocytes","volume":"19","author":"Carp\u00e9n\u00e9","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib113","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41374-019-0332-8","article-title":"Polydatin protects against lipopolysaccharide-induced endothelial barrier disruption via SIRT3 activation","volume":"100","author":"Wu","year":"2020","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.biopha.2021.112298_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2019.01.013","article-title":"Protective effects of polydatin against sulfur mustard-induced hepatic injury","volume":"367","author":"Zhang","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib115","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1111\/jcmm.13230","article-title":"Polydatin alleviated radiation-induced lung injury through activation of Sirt3 and inhibition of epithelial-mesenchymal transition","volume":"21","author":"Cao","year":"2017","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib116","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2013.10.006","article-title":"JAK2-targeted anti-inflammatory effect of a resveratrol derivative 2,4-dihydroxy-N-(4-hydroxyphenyl)benzamide","volume":"86","author":"Kim","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112298_bib117","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fneur.2013.00130","article-title":"Neuro-modulating effects of honokiol: a review","volume":"4","author":"Woodbury","year":"2013","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib118","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.3390\/molecules15096452","article-title":"Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders","volume":"15","author":"Shen","year":"2010","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2015.08.030","article-title":"Honokiol induces autophagy of neuroblastoma cells through activating the PI3K\/Akt\/mTOR and endoplasmic reticular stress\/ERK1\/2 signaling pathways and suppressing cell migration","volume":"370","author":"Yeh","year":"2016","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jgh.13853","article-title":"Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor \u03b3","volume":"33","author":"Zhong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"41","key":"10.1016\/j.biopha.2021.112298_bib121","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1038\/onc.2017.164","article-title":"Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3","volume":"36","author":"Sengupta","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-9-34","article-title":"Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells","volume":"9","author":"Luo","year":"2012","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.biopha.2021.112298_bib123","series-title":"Chapter l The Role of Docosahexaenoic Acid in the Evolution And Function of the Human Brain","author":"Kyle","year":"2002"},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib124","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.3390\/nu12092614","article-title":"Omega-3 polyunsaturated fatty acids EPA and DHA as an adjunct to non-surgical treatment of periodontitis: a randomized clinical trial","volume":"12","author":"Sta\u0144do","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2021.112298_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106961","article-title":"Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-\u03baB and MAPK pathways and activating the Nrf2 pathway in mice","volume":"88","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib126","first-page":"836","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib127","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/oby.2008.602","article-title":"Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives","volume":"17","author":"Rossmeisl","year":"2009","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib129","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2021.112298_bib131","first-page":"1","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic, Nature Reviews","volume":"89","author":"Geng","year":"2020","journal-title":"Endocrinology"},{"issue":"7689","key":"10.1016\/j.biopha.2021.112298_bib132","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature25010","article-title":"Structures of \u03b2-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling","volume":"553","author":"Lee","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21","volume":"26","author":"Owen","year":"2015","journal-title":"Trends Endocrinol. Metab. TEM"},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib134","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2021.112298_bib135","first-page":"4192","article-title":"Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys","volume":"9","author":"M","year":"2012","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib136","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib137","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.112298_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metab. Clin. Exp."},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111767","article-title":"Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes","volume":"9","author":"Lee","year":"2014","journal-title":"PloS One"},{"issue":"28","key":"10.1016\/j.biopha.2021.112298_bib140","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.biopha.2021.112298_bib141","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1042\/BCJ20160004","article-title":"FAP finds FGF21 easy to digest","volume":"473","author":"Gillum","year":"2016","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib142","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib143","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192146","article-title":"LY2405319, an analog of fibroblast growth factor 21 ameliorates \u03b1-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice","volume":"13","author":"Le","year":"2018","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib146","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.metabol.2014.11.009","article-title":"The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy","volume":"64","author":"Liu","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.biopha.2021.112298_bib147","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib148","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db11-0838","article-title":"FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents","volume":"61","author":"Mu","year":"2012","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib149","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2021.112298_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib152","first-page":"654","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic, nature reviews","volume":"16","author":"Geng","year":"2020","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib154","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-Klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib155","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib156","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.bbrc.2017.12.143","article-title":"Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition","volume":"495","author":"Nguyen","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2021.112298_bib157","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.biopha.2017.03.079","article-title":"Metformin mitigates carbon tetrachloride-induced TGF-\u03b21\/Smad3 signaling and liver fibrosis in mice","volume":"90","author":"Fan","year":"2017","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib158","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/ijmm.2015.2092","article-title":"MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis","volume":"35","author":"Katsura","year":"2015","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbrc.2019.03.077","article-title":"Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo","volume":"513","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Adnan","year":"2017","journal-title":"Ann. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib161","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/apt.14674","article-title":"Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease","volume":"47","author":"Chalasani","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib162","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2225-4110.106533","article-title":"Recent studies and progression of Yin Chen Hao (Y\u012bn Ch\u00e9n H\u0101o), a long-term used traditional Chinese medicine","volume":"3","author":"Hung","year":"2013","journal-title":"J. Tradit. Complement. Med."},{"key":"10.1016\/j.biopha.2021.112298_bib163","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1038\/srep06768","article-title":"Urinary metabolic profiling of rat models revealed protective function of scoparone against alcohol induced hepatotoxicity","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib164","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/omi.2012.0064","article-title":"Proteomics analysis of hepatoprotective effects for scoparone using MALDI-TOF\/TOF mass spectrometry with bioinformatics","volume":"17","author":"Zhang","year":"2013","journal-title":"Omics J. Integr. Biol."},{"issue":"51","key":"10.1016\/j.biopha.2021.112298_bib165","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","article-title":"Introduction to NF-kappaB: players, pathways, perspectives","volume":"25","author":"Gilmore","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib166","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/CT:6:2:111","article-title":"The NF-\u03baB regulatory network","volume":"6","author":"Brasier","year":"2006","journal-title":"Cardiovasc. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib167","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm2083","article-title":"Integrating cell-signalling pathways with NF-kappaB and IKK function","volume":"8","author":"Perkins","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"49","key":"10.1016\/j.biopha.2021.112298_bib168","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1038\/sj.onc.1203237","article-title":"The Rel\/NF-kappaB signal transduction pathway: introduction","volume":"18","author":"Gilmore","year":"1999","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib169","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.leu.2402482","article-title":"Nuclear transcription factor-kappaB as a target for cancer drug development","volume":"16","author":"Garg","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3181\/0707-MR-196","article-title":"Nuclear factor-kappaB activation: from bench to bedside","volume":"233","author":"Sethi","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112298_bib171","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.7150\/thno.42658","article-title":"PTPROt aggravates inflammation by enhancing NF-\u03baB activation in liver macrophages during nonalcoholic steatohepatitis","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2021.112298_bib172","first-page":"15","article-title":"Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives","volume":"8","author":"Ozaki","year":"2015","journal-title":"J. Inflamm. Res."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib173","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib174","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056100","article-title":"Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis","volume":"8","author":"Dixon","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2021.112298_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105797","article-title":"Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4\/NF-\u03baB signaling pathway in mice","volume":"75","author":"Liu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2021.112298_bib177","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biopha.2017.06.006","article-title":"Scoparone attenuates hepatic stellate cell activation through inhibiting TGF-\u03b2\/Smad signaling pathway","volume":"93","author":"Liu","year":"2017","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2021.112298_bib178","doi-asserted-by":"crossref","first-page":"109895","DOI":"10.1016\/j.biopha.2020.109895","article-title":"Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS\/P38\/Nrf2 axis and PI3K\/AKT\/mTOR pathway in macrophages","volume":"125","author":"Liu","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.biopha.2021.112298_bib179","doi-asserted-by":"crossref","DOI":"10.1007\/s00109-020-02017-3","article-title":"2,3,5,6-Tetramethylpyrazine protects retinal photoreceptors against endoplasmic reticulum stress by modulating ATF4-mediated inhibition of PRP aggregation","author":"Huang","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2021.112298_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.562084","article-title":"Tetramethylpyrazine ameliorates lipopolysaccharide-induced sepsis in rats via protecting blood-brain barrier, impairing inflammation and nitrous oxide systems","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112298_bib181","doi-asserted-by":"crossref","DOI":"10.1007\/s12031-020-01762-x","article-title":"The Tetramethylpyrazine analogue T-006 alleviates cognitive deficits by inhibition of tau expression and phosphorylation in transgenic mice modeling Alzheimer\u2019s disease","author":"Zhang","year":"2021","journal-title":"J. Mol. Neurosci. MN"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib182","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mce.2013.09.020","article-title":"Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K\/AKT and ERK pathways","volume":"382","author":"Zhang","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112298_bib183","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-017-4470-9","article-title":"Activation of Insulin-PI3K\/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis","volume":"62","author":"Cai","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.biopha.2021.112298_bib184","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.fct.2012.10.030","article-title":"Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils","volume":"52","author":"Ying","year":"2013","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/br.2012.27","article-title":"Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2021.112298_bib186","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.tiv.2013.01.014","article-title":"Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells","volume":"27","author":"Vidyashankar","year":"2013","journal-title":"Toxicol. Vitr. Int. J. Publ. Assoc. BIBRA"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib187","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/mnfr.201400913","article-title":"Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K\/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease","volume":"59","author":"Pisonero-Vaquero","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib188","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.22955","article-title":"Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent","volume":"50","author":"Chamulitrat","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.biopha.2021.112298_bib189","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1258\/ebm.2010.010160","article-title":"Extracellular signal-regulated kinases 1\/2 suppression aggravates transforming growth factor-beta1 hepatotoxicity: a potential mechanism for liver injury in methionine-choline deficient-diet-fed mice","volume":"235","author":"Wang","year":"2010","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2021.112298_bib190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fimmu.2019.00017","article-title":"Spred2 regulates high fat diet-induced adipose tissue inflammation, and metabolic abnormalities in mice","volume":"10","author":"Ohkura","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib191","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib192","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib193","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ceca.2009.11.003","article-title":"Succinate modulates Ca(2+) transient and cardiomyocyte viability through PKA-dependent pathway","volume":"47","author":"Aguiar","year":"2010","journal-title":"Cell Calcium"},{"key":"10.1016\/j.biopha.2021.112298_bib194","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12964-014-0078-2","article-title":"Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation","volume":"12","author":"Aguiar","year":"2014","journal-title":"Cell Commun. Signal. CCS"},{"issue":"7","key":"10.1016\/j.biopha.2021.112298_bib195","first-page":"2526","article-title":"Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney","volume":"118","author":"Toma","year":"2008","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib196","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1681\/ASN.2008070740","article-title":"Activation of the succinate receptor GPR91 in macula densa cells causes renin release","volume":"20","author":"Vargas","year":"2009","journal-title":"J. Am. Soc. Nephrol. JASN"},{"issue":"5","key":"10.1016\/j.biopha.2021.112298_bib197","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41590-019-0372-7","article-title":"SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity","volume":"20","author":"Keiran","year":"2019","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112298_bib198","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18632\/aging.100563","article-title":"Deficiency in the metabolite receptor SUCNR1 (GPR91) leads to outer retinal lesions","volume":"5","author":"Favret","year":"2013","journal-title":"Aging"},{"issue":"21","key":"10.1016\/j.biopha.2021.112298_bib199","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1073\/pnas.1720758115","article-title":"Activation of intestinal tuft cell-expressed Sucnr1 triggers type 2 immunity in the mouse small intestine","volume":"115","author":"Lei","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2021.112298_bib200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.immuni.2018.06.016","article-title":"Detection of succinate by intestinal tuft cells triggers a type 2 innate immune circuit","volume":"49","author":"Nadjsombati","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2021.112298_bib201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/10408363.2011.596521","article-title":"Non-alcoholic fatty liver disease","volume":"48","author":"Smith","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112298_bib202","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.2337\/dc20-0460","article-title":"Impaired succinate response to a mixed meal in obesity and type 2 diabetes is normalized after metabolic surgery","volume":"43","author":"Astiarraga","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:34:16Z","timestamp":1760099656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221010829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":202,"alternative-id":["S0753332221010829"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112298","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Foresight regarding drug candidates acting on the succinate\u2013GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112298"}}